研究单位：[1]Beijing InnoCare Pharma Tech Co., Ltd.[2]Cancer Institute and Hospital, Chinese Academy of Medical Sciences[3]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,100000[4]Beijing Hospital,Beijing,Beijing,China,100000[5]Beijing Shijitan hospital, capital medical university,Beijing,Beijing,China,100000[6]Cancer hospital, Chinese academy of medical sciences,Beijing,Beijing,China,100000[7]Affiliated Hospital of Hebei University,Baoding,Hebei,China,100000[8]Henan Tumor Hospital,Zhengzhou,Henan,China,100000[9]Hunan Cancer Hospital,Changsha,Hunan,China,100000[10]First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,100000[11]The First Hospital of Jilin University,Changchun,Jilin,China,100000[12]Tianjin People's Hospital,Tianjin,Tianjin,China,100000
Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma
